Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria

Hepatitis B Clinical Trial

Official title:

Beijing Center for Disease Prevention and Control

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04264312
• Other study ID #: BJCDCWJ202001
• Status: Completed
• Start date: July 28, 2017
• Est. completion date: January 10, 2020

Study information

• Verified date: February 2020
• Source: Centers for Disease Control and Prevention, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.

Description:

Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76220
• Est. completion date: January 10, 2020
• Est. primary completion date: September 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

• older than 25 years old;

• Residents with medical insurance coverage lived in Beijing more than 6 months .

Exclusion Criteria:

• Persons with pacemakers;

• Pregnant women;

• Persons with ascites;

• The one whose wound was not cured at the right upper abdomen

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B

Locations

Country	Name	City	State
China	Changping District Center for Disease Prevention and Control	Beijing
China	Chaoyang District Center for Disease Control and Prevention	Beijing	Beijing
China	Daxing District Center for Disease Prevention and Control	Beijing	Beijing
China	Dongcheng District Center for Disease Control and Prevention	Beijing	Beijing
China	FangShan District Center for Disease Prevention and Control	Beijing
China	Fengtai District Center for Disease Control and Prevention	Beijing	Beijing
China	Haidian District Center for Disease Prevention and Control	Beijing
China	Huairou District Center for Disease Prevention and Control	Beijing	Beijing
China	Miyun District Center for Disease Prevention and Control	Beijing
China	Tongzhou District Center for Disease Prevention and Control	Beijing
China	Xicheng District Center for Disease Prevention and Control	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Wu Jiang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HBsAg positive rate	Complete HBsAg tests for more than 60,000 people over the age of 25 in Beijing	Baseline
Primary	Average rate of chronic hepatitis B accepting antiviral treatment	The one who is eligible for HBV treated criteria based on community in 25 and over years old in Beijing.	Baseline